An immunoadsorbent and a composite affinity column for purifying fumonisin B1, anguidin, T-2 toxin, zearalenone, and vomitoxin. The immunoadsorbent includes a solid phase carrier, and a fumonisin B1 monoclonal antibody, an anguidin monoclonal antibody, a T-2 toxin monoclonal antibody, a zearalenone monoclonal antibody and a vomitoxin monoclonal antibody which are coupled to the solid phase carrier, the anguidin monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell strain DAS5G11E7 having an accession number of CCTCCNO:C201881. The affinity column can be used for high performance liquid chromatography-mass spectrometry detection of the fumonisin B1, the anguidin, the T-2 toxin, the zearalenone and the vomitoxin, and has stable performance. Furthermore, an economical, quick, precise and safe detection method is established of the basis of the affinity column, and can be used for purifying and detecting samples of the five toxins without mutual interference and influence.

Disclosed herein are methods and assays for the detection and/or quantification of one or more proteins or substances of interest in a sample, such as a plant, human, insect, microorganism or mammalian sample.

The invention relates to a method for predicting yield performance of a crop plant, comprising the steps of receiving metabolite measurements of the crop plant; determining new metabolite features by combining the received metabolite measurements, wherein at least one new metabolite feature is based on a classified average; providing the new metabolite features to a trained machine learning model; and determining yield performance of the crop plant using the provided model. It also relates to a method for training a machine learning model for predicting yield performance of a crop plant; a control unit configured to execute the method for predicting yield performance; to a plant breeding method and a farming method that apply said method; and the use of new metabolite features as determined in said method for prediction of yield performance.

Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods. In certain embodiments, the Aspergillus protease is Asp f2, and the Aspergillus infection is caused A. fumigatus, A. flavus, A. versicolor, A. niger, or A. terreus. Also provided herein are antibodies and kits for use in these methods, including novel antibodies specific for Asp f2.

A pesticidal protein class of PirA, PirB, and PirAB fusion proteins exhibiting toxic activity against Coleopteran, Lepidopteran, and Hemipteran pest species is disclosed. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding the PirA, PirB, and PirAB fusion proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Coleopteran, Lepidopteran, and Hemipteran infestation are provided which contain recombinant nucleic acid sequences encoding the PirA, PirB, and PirAB fusion proteins. Methods for detecting the presence of the recombinant nucleic acid sequences or the proteins of the present invention in a biological sample, and methods of controlling Coleopteran, Lepidopteran, and Hemipteran species pests using the PirA, PirB, and PirAB fusion proteins are also provided.

The present invention relates to an immunodiagnostic kit and method for co-detection of R. solanacearum and F. oxysporum that cause bacterial wilt disease and fungal wilt disease, respectively, which are difficult to accurately diagnose due to the overlapping onset time and similar disease symptoms thereof in plants, and to a test kit for determining a pathogen of plant wilt disease in an early stage by using a semi-quantitative lateral flow immunodiagnostic technique to detect the pathogen in a plant juice. In addition, the kit and method can semi-quantitatively measure a density of a pathogen to determine a degree of infection to the plant. According to the configuration of the present invention, the kit and method can simultaneously detect R. solanacearum and F. oxysporum in a separate manner and as such, is helpful in accurately diagnosing diseases more easily within a shorter period of time than conventional observation by naked eye or microorganism separation and identification methods. Therefore, the present invention can advantageously contribute to the selection by farmers of chemicals for treatment of plant diseases.

Provided herein is an antibody as well as chimeric antigen receptor (CAR) to the Aspergillus antigen p60-binding domain. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of fungal infections and cancer.

A testing method is described for use in undertaking a test upon a sample (10) for the presence of a specific microbiological material, the method comprising the steps of combining the sample (10) with a viability-preserving medium, optionally with an enrichment medium (12) selected to promote growth and/or reproduction of the specific microbiological material within the sample (10) and incubating the sample (10) and enrichment material (12), undertaking a separation process to separate the live specific microbiological material from the sample (10), and testing the separated material for the presence of the specific microbiological material. An apparatus for use in the method is also described.

The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.

The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).